ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...

ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021 ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...